LISATA THERAPEUTICS, INC.
No SEC Form 4 filings for $LSTA in the last 30 days.
See all $LSTA insider activity →Lisata Therapeutics (LSTA) acquired Marea Therapeutics and raised $225M in private financing. The deal expands Lisata's portfolio into cardioendocrine therapeutics. Proceeds will fund clinical trials for MAR001/005 and MAR002, with data expected in Q4 2027. LSTA shares rose 20.41% to $1.77. Post-transaction, former Marea equity holders will own 59.54% of Lisata.
Lisata Therapeutics (LSTA) acquired Marea Therapeutics in a stock-for-stock deal, raising $225M in private placement. Lisata shares surged 20% after the news. The acquisition focuses on advancing Marea's cardioendocrine disease treatments, with key clinical milestones expected in 2027. Investors include RA Capital, Forbion, and Third Rock Ventures.
LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next - generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical produc
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning LSTA (LISATA THERAPEUTICS, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent LSTA coverage spans mergers & acquisitions, corporate actions and financial news.
The deal expands Lisata's pipeline and dilutes existing shareholders, but the large capital raise and acquisition provide near‑term upside potential.
The deal expands Lisata's pipeline and dilutes existing shareholders, while the large capital raise provides runway for upcoming trials.
The deal expands Lisata's pipeline and dilutes existing shareholders, while the large financing provides runway to 2028.
Restructuring and cost cuts can reduce burn and extend runway, but also signal execution risk after a failed deal.
The merger termination and cost-cutting signal heightened execution and financing risk, while the strategic review keeps optionality open.
AlphAI scores every news story that mentions LSTA with an AI model for sentiment and relevance, and aggregates insider trades from LISATA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lisata Therapeutics (LSTA) acquired Marea Therapeutics and raised $225M in private financing. The deal expands Lisata's portfolio into cardioendocrine therapeutics. Proceeds will fund clinical trials for MAR001/005 and MAR002, with data expected in Q4 2027. LSTA shares rose 20.41% to $1.77. Post-transaction, former Marea equity holders will own 59.54% of Lisata.
2 min readLisata Therapeutics (LSTA) acquired Marea Therapeutics in a stock-for-stock deal, raising $225M in private placement. Lisata shares surged 20% after the news. The acquisition focuses on advancing Marea's cardioendocrine disease treatments, with key clinical milestones expected in 2027. Investors include RA Capital, Forbion, and Third Rock Ventures.
2 min readLISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next - generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical produc
2 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readLisata Therapeutics (LSTA) said its merger with Kuva Acquisition Corp was terminated and it has sued Kuva in Delaware Chancery for breach, seeking damages including a $2 million termination fee. The board is reviewing strategic options. To cut costs, it reduced its workforce by 72%. LSTA stock closed at $1.04.
4 min readLisata Therapeutics (NASDAQ:LSTA) said it filed suit in Delaware Chancery after Kuva Labs and Kuva Acquisition Corp terminated their March 6, 2026 merger agreement. Lisata alleges breach and seeks damages plus a $2 million termination fee. It also cut full-time roles by about 72% to preserve cash while evaluating strategic alternatives. Lead candidate is certepetide.
4 min readLISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 2.05 Costs Associated with Exit or Disposal Activities. On August 3, 2026, the board of directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) approved a reduction in workforce by approximately 72%, effective immediately. The decision was based on cost-reductio
4 min readLISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0000320017 NASDAQ 0000320017 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 24, 2026 Date of Report (date of earliest event rep
3 min readLISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0000320017 NASDAQ 0000320017 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 16, 2026 Date of Report (date of earliest event rep
2 min readLisata Therapeutics agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus contingent value rights up to $3.00 per share tied to certepetide drug milestones. Kuva’s tender offer began June 10 and runs until July 10, 2026. Lisata’s board unanimously recommended tendering; deal closes in Q3 2026 and Lisata will be delisted.
4 min read
